Gene Therapy Market
Gene Therapy Market Forecasts to 2030 - Global Analysis By Vector (Non-Viral Vectors and Viral Vectors), Gene Type (Antigen, Cytokine, Tumor Suppressor and Other Gene Types), Delivery Method (In Vivo and Ex Vivo), Application, End User and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $8.80 BN |
|
Projected Year Value (2030) |
US $32.66 BN |
|
CAGR (2023 - 2030) |
20.6% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Gene Therapy Market is accounted for $8.80 billion in 2023 and is expected to reach $32.66 billion by 2030 growing at a CAGR of 20.6% during the forecast period. Human gene therapy is a procedure that alters a person's genes to treat or cure disease. It aims to change or regulate a gene's expression or the biological characteristics of live cells for therapeutic purpose. Inactivating a disease-causing gene that is not working correctly, replacing a disease-causing gene with a healthy copy of the gene, and introducing a new or modified gene into the body to cure a disease are some of the ways that gene therapies can operate. Products utilizing gene therapy are being investigated for the treatment of diseases including cancer, genetic disorders, and infectious diseases.
According to the ACS 'Cancer Facts & Figures 2022', around 1,918,030 new cancer cases and 609,360 deaths due to cancers are estimated to be reported in the United States in 2022. In the treatment of cancer, various gene therapy strategies are currently employed.
Market Dynamics:
Driver:
Novel gene therapy techniques
Ailments that previously only received temporary therapies now have permanent remedies because to gene therapy. Gene therapy failed for a very long time; nevertheless, in recent years, successful and long-lasting treated instances have been documented. Promising results have been reached for a wide range of genetic ailments, including blood abnormalities, immunological inadequacies, eyesight problems, nerve cell regeneration, metabolic disorders, and several cancer kinds. Gene therapy has the potential to be a personalized treatment that can "cure" a range of diseases with more specificity and fewer negative effects. Gene therapy is the practice of transferring genetic material to a patient in order to treat a disease or, at the very least, improve their clinical state which enhances the growth of the market.
Restraint:
Gene therapy products are subject to strict restrictions
Globally, the use of gene therapy is expanding quickly because to the aging population and a number of chronic diseases that can be avoided with early detection and prompt treatment. Likewise, in order to receive clearance from higher authorities for the product's introduction in an area, gene therapy market participants must go by a set of rules. One of the most challenging duties among all the procedures is adhering to these strict restrictions. Different gene therapy medicines have different pre-market approval levels depending on the nation.
Opportunity:
Increasing rates of neurological and oncological disorders
Rare genetic illnesses are becoming more common among people all over the world. The National Organization for Rare Diseases (NORD) estimates that 1 in 10,000 live births in the United States occur each year due to spinal muscular atrophy. The profession has experienced technological developments that have made it easier to cure diseases that were formerly thought to be incurable. On the other hand, one of the most common diseases in the world is cancer. These gene treatments assist individuals who are especially susceptible to developing specific forms of cancer due to genetic mutations handed down from the previous generation in preventing the disease.
Threat:
High cost of treatment
In order to treat an illness, a patient's genome may be altered, deleted, or added to as part of a novel medical procedure known as gene therapy. Gene therapy has already demonstrated significant promise for the treatment and even cure of once-intractable disorders, despite the fact that it is still in its infancy. In many countries, the cost of gene therapy is still largely unregulated and decided on a case-by-case basis, typically focused on a single upfront payment.
Covid-19 Impact
Due to a decrease in the number of cancer patients visiting hospitals and clinics for gene therapy (ICI), which resulted in a decrease in demand for gene therapy products, COVID-19's overall impact on the market for gene therapy remained unfavorable. For instance, the NCBI estimates that the number of cancer patients in the U.S. would drop by around 50% by 2020, and that the market's demand for gene therapy products will also drop by about 50% during COVID-19.
The viral vectors segment is expected to be the largest during the forecast period
The viral vectors segment is estimated to have a lucrative growth, due to the ability to control viral vectors to express therapeutic genes makes them the most efficient method of gene transfer for altering a particular cell type or tissue. Several virus types are being researched right now for their potential to be used to transfer genes to cells for either temporary or permanent transgenic expression. In order to circumvent immune monitoring by an infected host, viruses have evolved to become extremely effective at delivering nucleic acids to a limited range of cell types. These characteristics make viruses appealing gene delivery vectors for gene therapy, thus propelling the growth of the market.
The hospitals segment is expected to have the highest CAGR during the forecast period
The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period, as the prevalence is caused by the treatment modalities' great availability and accessibility in such institutions. Throughout the projection period, it is expected that this market segment will continue to rule. Due to the rise of independent clinics offering cutting-edge treatments for neurological and cancer disorders, the clinics market is also expected to expand.
Region with largest share:
North America is projected to hold the largest market share during the forecast period owing to the number of approvals and the amount of money made throughout the projected period, and the market will continue to grow as more major and small businesses make R&D expenditures in the creation of medications for optimum therapy. The market is also being driven by the governments' expanding investment levels and the rising incidence of certain ailments. The Spinal Muscular Atrophy Foundation estimates that between 10,000 and 25,000 children and adults in the United States will have spinal muscular atrophy by the year 2020, making it a reasonably prevalent condition.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the country's sizable population's unmet medical demands and rising need for breakthrough technology in the management of uncommon but steadily escalating diseases. Due to the easy access to resources, the presence of big corporations locally, and rising government funding, the Asia Pacific market for the commercial use of genetic treatments is predicted to have considerable expansion over the projected period.
Key players in the market
Some of the key players profiled in the Gene Therapy Market include Amgen Inc. , Biogen Inc., Bluebird Bio Inc., Gilead Sciences Inc., Novartis AG, F. Hoffmann-La Roche Ltd, UniQure NV, Abeona Therapeutics Inc., Generation Bio, Poseida Therapeutics, Astellas Pharma, Voyager Therapeutics Inc., Jazz Pharmaceuticals, Inc, GlaxoSmithKline plc, Spark Therapeutics Inc, Sarepta Therapeutics, Orchard Therapeutics, Shenzhen SiBiono GeneTech, Shanghai Sunway Biotech Co. Ltd. and CRISPR Therapeutics AG
Key Developments:
In August 2023, Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years. The results were presented in a late-breaking session at the European Society of Cardiology (ESC) Congress 2023 in Amsterdam.
In July 2023, Biogen to Acquire Reata Pharmaceuticals, Reata has made significant advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases.
In February 2023, Kite, a Gilead Company announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
Vectors Covered:
• Non-Viral Vectors
• Viral Vectors
Gene Types Covered:
• Antigen
• Cytokine
• Tumor Suppressor
• Suicide
• Deficiency
• Growth factors
• Receptors
• Other Gene Types
Delivery Methods Covered:
• In Vivo
• Ex Vivo
Applications Covered:
• DMD (Duchenne Muscular Dystrophy)
• Neurological Diseases
• Cancer
• Hepatological Diseases
• Rare Diseases
• Oncological Disorders
• Acute Lymphoblastic Leukemia (ALL)
• Peripheral arterial disease
• Other Applications
End Users Covered:
• Cancer Institutes
• Hospitals
• Research Institutes
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Gene Therapy Market, By Vector
5.1 Introduction
5.2 Non-Viral Vectors
5.2.1 Oligonucleotides
5.2.2 Other Non-Viral Vectors
5.3 Viral Vectors
5.3.1 Retro Viral Vectors
5.3.2 Adeno-Associated Virus Vectors
5.3.3 Lentiviral Vector
5.3.4 Herpes Virus Vector
5.3.5 Other Viral Vectors
6 Global Gene Therapy Market, By Gene Type
6.1 Introduction
6.2 Antigen
6.3 Cytokine
6.4 Tumor Suppressor
6.5 Suicide
6.6 Deficiency
6.7 Growth factors
6.8 Receptors
6.9 Other Gene Types
7 Global Gene Therapy Market, By Delivery Method
7.1 Introduction
7.2 In Vivo
7.3 Ex Vivo
8 Global Gene Therapy Market, By Application
8.1 Introduction
8.2 DMD (Duchenne Muscular Dystrophy)
8.3 Neurological Diseases
8.4 Cancer
8.5 Hepatological Diseases
8.6 Rare Diseases
8.7 Oncological Disorders
8.8 Acute Lymphoblastic Leukemia (ALL)
8.9 Peripheral arterial disease
8.10 Other Applications
9 Global Gene Therapy Market, By End User
9.1 Introduction
9.2 Cancer Institutes
9.3 Hospitals
9.4 Research Institutes
9.5 Other End Users
10 Global Gene Therapy Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Amgen Inc.
12.2 Biogen Inc.
12.3 Bluebird Bio Inc.
12.4 Gilead Sciences Inc.
12.5 Novartis AG
12.6 F. Hoffmann-La Roche Ltd
12.7 UniQure NV
12.8 Abeona Therapeutics Inc.
12.9 Generation Bio
12.10 Poseida Therapeutics
12.11 Astellas Pharma
12.12 Voyager Therapeutics Inc.
12.12 Jazz Pharmaceuticals, Inc
12.14 GlaxoSmithKline plc
12.15 Spark Therapeutics Inc
12.16 Sarepta Therapeutics
12.17 Orchard Therapeutics
12.18 Shenzhen SiBiono GeneTech
12.19 Shanghai Sunway Biotech Co. Ltd.
12.20 CRISPR Therapeutics AG
List of Tables
1 Global Gene Therapy Market Outlook, By Region (2021-2030) ($MN)
2 Global Gene Therapy Market Outlook, By Vector (2021-2030) ($MN)
3 Global Gene Therapy Market Outlook, By Non-Viral Vectors (2021-2030) ($MN)
4 Global Gene Therapy Market Outlook, By Oligonucleotides (2021-2030) ($MN)
5 Global Gene Therapy Market Outlook, By Other Non-Viral Vectors (2021-2030) ($MN)
6 Global Gene Therapy Market Outlook, By Viral Vectors (2021-2030) ($MN)
7 Global Gene Therapy Market Outlook, By Retro Viral Vectors (2021-2030) ($MN)
8 Global Gene Therapy Market Outlook, By Adeno-Associated Virus Vectors (2021-2030) ($MN)
9 Global Gene Therapy Market Outlook, By Lentiviral Vector (2021-2030) ($MN)
10 Global Gene Therapy Market Outlook, By Herpes Virus Vector (2021-2030) ($MN)
11 Global Gene Therapy Market Outlook, By Other Viral Vectors (2021-2030) ($MN)
12 Global Gene Therapy Market Outlook, By Gene Type (2021-2030) ($MN)
13 Global Gene Therapy Market Outlook, By Antigen (2021-2030) ($MN)
14 Global Gene Therapy Market Outlook, By Cytokine (2021-2030) ($MN)
15 Global Gene Therapy Market Outlook, By Tumor Suppressor (2021-2030) ($MN)
16 Global Gene Therapy Market Outlook, By Suicide (2021-2030) ($MN)
17 Global Gene Therapy Market Outlook, By Deficiency (2021-2030) ($MN)
18 Global Gene Therapy Market Outlook, By Growth factors (2021-2030) ($MN)
19 Global Gene Therapy Market Outlook, By Receptors (2021-2030) ($MN)
20 Global Gene Therapy Market Outlook, By Other Gene Types (2021-2030) ($MN)
21 Global Gene Therapy Market Outlook, By Delivery Method (2021-2030) ($MN)
22 Global Gene Therapy Market Outlook, By In Vivo (2021-2030) ($MN)
23 Global Gene Therapy Market Outlook, By Ex Vivo (2021-2030) ($MN)
24 Global Gene Therapy Market Outlook, By Application (2021-2030) ($MN)
25 Global Gene Therapy Market Outlook, By DMD (Duchenne Muscular Dystrophy) (2021-2030) ($MN)
26 Global Gene Therapy Market Outlook, By Neurological Diseases (2021-2030) ($MN)
27 Global Gene Therapy Market Outlook, By Cancer (2021-2030) ($MN)
28 Global Gene Therapy Market Outlook, By Hepatological Diseases (2021-2030) ($MN)
29 Global Gene Therapy Market Outlook, By Rare Diseases (2021-2030) ($MN)
30 Global Gene Therapy Market Outlook, By Oncological Disorders (2021-2030) ($MN)
31 Global Gene Therapy Market Outlook, By Acute Lymphoblastic Leukemia (ALL) (2021-2030) ($MN)
32 Global Gene Therapy Market Outlook, By Peripheral arterial disease (2021-2030) ($MN)
33 Global Gene Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
34 Global Gene Therapy Market Outlook, By End User (2021-2030) ($MN)
35 Global Gene Therapy Market Outlook, By Cancer Institutes (2021-2030) ($MN)
36 Global Gene Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
37 Global Gene Therapy Market Outlook, By Research Institutes (2021-2030) ($MN)
38 Global Gene Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
